Evidence map›Paper›PMID 35186807›Full record

ArticleCanadian journal of gastroenterology & hepatology2022

Therapeutic Effects of Milk Thistle (

Aida Doostkam, Mohammad Fathalipour, Mohammad Hossein Anbardar, Azar Purkhosrow, Hossein Mirkhani

Abstract read
In one paragraph

Article in Canadian journal of gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Preventive and Therapeutic Effects ofACS pharmacology & translational science · 2023
    Article
  9. Diabetes and diabesity in the view of proteomics, drug, and plant-derived remedies.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aida DoostkamShiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0003-3348-573X
Mohammad FathalipourDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.ORCID 0000-0002-4568-7024
Mohammad Hossein AnbardarDepartment of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0002-2317-0737
Azar PurkhosrowDepartment of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0003-2399-6878
Hossein MirkhaniDepartment of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID 0000-0002-7433-1174

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt present, nonalcoholic fatty liver disease (NAFLD) does not have an approved pharmacologic therapy. The present study investigated the protective effects and possible mechanisms of milk thistle (

methodsThe NAFLD was established in rats after four weeks of type 2 diabetes induction. The animals were treated with pharmaceutical preparations of milk thistle (Livergol®) and artichoke (Atheromod-B®) extracts for eight weeks. After the end of the intervention, oral glucose tolerance, the serum parameters of oxidative stress, liver functional tests, and lipid profiles were evaluated. Histopathological changes were assessed by hematoxylin and eosin staining.

resultsTreatment with preparations of milk thistle and artichoke nonsignificantly improved glucose tolerance in diabetic rats. Both preparations significantly improved serum superoxide dismutase activity and the level of malondialdehyde. Although treatment with milk thistle reduced serum activity of aspartate aminotransferase and serum levels of triglyceride (TG), total cholesterol, and low-density lipoprotein-cholesterol, artichoke extracts only attenuated the serum level of TG. Milk thistle also effectively protected the liver from histological changes.

conclusionsMilk thistle could be a promising pharmacological option for the treatment of NAFLD. Nonetheless, long-term randomized clinical trials are necessary to confirm the observed results.

Indexed as

Biological ProductsCynara scolymusDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseAnimalsAntioxidantsCholesterolHumansPlant ExtractsRatsSilybum marianumTriglyceridesAntioxidantsBiological ProductsCholesterolPlant ExtractsTriglycerides

Identifiers

PMID35186807
PMCPMC8856812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.